摘要
目的评价普瑞巴林联合替扎尼定对带状疱疹后神经痛(PHN)的治疗效果及安全性。方法收集2019年4月至2020年3月就诊于青岛大学附属医院疼痛诊疗科的PHN患者,30~70岁,性别不限,病程3~6个月,共40例。按照随机数字表法将其分为普瑞巴林组和联合用药组,每组20例。两组接受基础治疗(甲钴胺1.5 mg/d,3次/d)的同时,普瑞巴林组患者口服普瑞巴林,150~300 mg/d,2次/d,持续12周;联合用药组患者口服普瑞巴林基础上,联合口服盐酸替扎尼定6 mg/d,3次/d,持续12周。记录两组患者基础状态及用药后2、4、12周疼痛数字等级评分(NRS),以及用药后12周的优良率、不良反应、普瑞巴林日用量、镇痛药物日用量及镇痛药物补救患者例数。结果与基础值比较,两组患者治疗后各时点NRS评分均明显降低(P均<0.05);与普瑞巴林组比较,联合用药组用药后各时点NRS评分均降低(P均<0.05)。治疗后12周时,与普瑞巴林组比较,联合用药组优良率较高[90%(18/20例)比80%(16/20例),χ^(2)=3.962,P=0.047],普瑞巴林日用量较少[225.0(262.5)mg比150.0(0)mg,Z=-2.080,P=0.038],使用曲马多补救的患者例数较少(2例比5例,χ^(2)=4.680,P=0.031)。但是两组间不良反应差异无统计学意义(1例比2例,χ^(2)=0.351,P=0.553)。结论普瑞巴林联合替扎尼定治疗PHN疗效优于单独应用普瑞巴林,且不增加不良反应。
Objective To evaluate the efficacy and safety of pregabalin combined with tizanidine in the treatment of patients with postherpetic neuralgia(PHN).Methods A total of 40 patients with PHN,30-70 years old,both gender,course of disease 3 to 6 months,were randomly divided into the pregabalin group and the combination group(n=20)in the Department of Pain Management,the Affiliated Hospital of Qingdao University from April 2019 to March 2020.All patients were received basic treatment(mecobalamine 1.5 mg/d,3 times/d).The patients were received pregabalin(150-300 mg/d,2 times/d for 12 weeks)in the pregabalin group,while patients were received pregabalin(150-300 mg/d,2 times/d for 12 weeks)combined with tizanidine hydrochloric(6 mg/d,3 times/d for 12 weeks)in the combination group.NRS was recorded at the baseline,and at 2,4,and 12 weeks after the treatment.At the 12 weeks after the treatment,the excellent and good rate,adverse reactions,the daily dosage of pregabalin and analgesics,and the number of patients using remedial analgesics were observed.Results Compared with the baseline,NRS was significantly decreased at each time point after the treatment in both groups(all P<0.05).NRS was lower significantly at each time point after the treatment in the combination group than that in the pregabalin group(all P<0.05).At 12 weeks after drug treatment,the excellent and good rate was higher[90%(18/20 cases)vs.80%(16/20 cases),χ^(2)=3.962,P=0.047)],the daily dosage of pregabalin was fewer[225.0(262.5)mg vs.150.0(0)mg,Z=-2.080,P=0.038],the number of patients using tramadol was fewer in the combination medication group than those in the pregabalin group(2 cases vs.5 cases,χ^(2)=4.680,P=0.031).However,there was no significant difference in adverse reactions between the two groups(1 case vs.2 cases,χ^(2)=0.351,P=0.553).Conclusion Efficacy of pregabalin combined with tizanidine hydrochloride is superior to pregabalin alone in the treatment of patients with PHN,without more severe adverse reactions.
作者
孟超
张冰
于俊敏
徐凤和
刘传圣
尹燕伟
Meng Chao;Zhang Bing;Yu Junmin;Xu Fenghe;Liu Chuansheng;Yin Yanwei(Department of Pain Management,the Affiliated Hospital of Qingdao University,Qingdao City,Shandong Province 266000,China;Department of Anesthesiology,the Affiliated Hospital of Qingdao University,Qingdao City,Shandong Province 266000,China)
出处
《中华疼痛学杂志》
2021年第2期186-190,共5页
Chinese Journal Of Painology
